Images List Premium Download Classic

Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
Askat Inc.
May 10, 2018 - N°20180125832

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s). The method may include a pharmaceutical composition comprising the ...
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical ...
Deuterx, Llc
May 03, 2018 - N°20180117026

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.
Modulators of farnesoid x receptor and methods for the use thereof
Xiamen University
May 03, 2018 - N°20180116993

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; ...
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor ...
Remd Biotherapeutics, Inc.
March 22, 2018 - N°20180079820

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e. G., fully human antibodies, that specifically bind to and ...
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030083

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (i) can be used to treat and/or ...
Heterocyclic compounds and methods of use
Medivation Technologies, Inc.
February 01, 2018 - N°20180028518

This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (nash); elevated cholesterol levels, and insulin resistance.
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Uses of mito-ob transgenic mice
University Of Manitoba
March 30, 2017 - N°20170089888

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (nash) and hepatocarcinogenesis over time. Also described is a mutant mito-ob mouse that develops lymphadenopathy and histiocytosis.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Glucagon and glp-1 co-agonist compounds
Eli Lilly And Company
December 22, 2016 - N°20160368960

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Differential diagnosis of liver disease
The Regents Of The University Of California
October 20, 2016 - N°20160305925

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls. Specifically, the invention relates to ...
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
Intekrin Therapeutics, Inc.
September 15, 2016 - N°20160263098

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention ...
Engineered polypeptides having enhanced duration of action and reduced immunogenicity
July 21, 2016 - N°20160207974

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis
Yale University
May 19, 2016 - N°20160139149

Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease. Chi3l1 levels can also be used to monitor treatment progress in patients having nash. Also disclosed herein are compositions and methods for treating nash by targeting chi3l1.
Engineered polypeptides having enhanced duration of action
Aegerion Pharmaceuticals, Inc.
May 19, 2016 - N°20160137709

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Highly soluble leptins
Aegerion Pharmaceuticals, Inc.
March 24, 2016 - N°20160083446

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii). Additional diseases and disorders which can be treated by the compounds and ...
Method of treating advanced non-alcoholic steatohepatitis
November 12, 2015 - N°20150322004

Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for inhibiting or treating advanced nonalcoholic steatohepatitis, conditions leading to or arising from it, and/or negative effects of each thereof.
Novel biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease ...
Mcbi, Inc.
August 06, 2015 - N°20150219672

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to ...
Anti-angptl3 antibodies and uses thereof
Regeneron Pharmaceuticals, Inc.
July 16, 2015 - N°20150197564

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hangptl3 ...
Methods for the treatment of nonalcoholic steatohepatitis
Universite Paris Descartes
February 26, 2015 - N°20150057332

The present invention relates to the treatment of nonalcoholic steatohepatitis (nash), in particular to a compound that inhibits mir-21 expression for use in the treatment of nonalcoholic steatohepatitis.
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
October 09, 2014 - N°20140303018

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
Loading